Literature DB >> 7522978

Intracellular metabolism of 5-methyltetrahydrofolate and 5-formyltetrahydrofolate in a human breast-cancer cell line.

D M Voeller1, C J Allegra.   

Abstract

This report describes the intracellular metabolism of 5-methyltetrahydrofolate (5-methyl-H4PteGlu) and 5-formyltetrahydrofolate (5-formyl-H4PteGlu) to the various folate forms and their respective polyglutamated states in the MCF-7 human breast-cancer cell line. The intracellular folate distribution observed in MCF-7 cells treated with 5-methyl-H4PteGlu was similar to that seen in cells treated with 5-formyl-H4PteGlu. In cells exposed to 5-formyl-H4PteGlu for 24 h, the folate pool consisted of 103 +/- 10 pmol/mg 10-formyl-H4PteGlu, 120 +/- 18 pmol/mg H4PteGlu, and 71 +/- 18 pmol/mg 5-methyl-H4PteGlu versus 88 +/- 5, 54 +/- 20 and 87 +/- 10 pmol/mg, respectively, for cells exposed to 5-methyl-H4PteGlu. Only the difference seen in H4PteGlu levels between cells exposed to either 5-methyl-H4PteGlu or 5-formyl-H4PteGlu reached statistical significance (P < 0.05). In the absence of vitamin B12, exposure to 5-methyl-H4PteGlu resulted in 154 +/- 17 pmol/mg 5-methyl-H4PteGlu along with only 8 +/- 5 pmol/mg 10-formyl-H4PteGlu and 4 +/- 2 pmol/mg H4PteGlu, thus demonstrating the marked dependence on vitamin B12 for the metabolism of 5-methyl-H4PteGlu to the other intracellular folates. 5-10-Methylene- H4PteGlu (2 +/- 1.3 pmol/mg) was detected only in cells exposed to 5-formyl-H4PteGlu for 24 h, not in cells treated with 5-methyl-H4PteGlu. The profile of polyglutamates detected in cells treated with either 5-formyl-H4PteGlu or 5-methyl-H4PteGlu for 24 h was not significantly different, although cells treated with 5-methyl-H4PteGlu tended to have less conversion to the higher polyglutamates (Glu3-Glu5) as compared with those treated with 5-formyl-H4PteGlu. In 5-methyl-H4PteGlu-treated cells grown in the absence of vitamin B12, the pentaglutamate was the only polyglutamate form detected, accounting for only 11% of the total folate pool. Since there does not appear to be a greater formation of the optimal reduced-folate forms necessary to achieve enhanced thymidylate synthase (TS) inhibition through ternary-complex formation in cells exposed to 5-methyl-H4PteGlu versus 5-formyl-H4PteGlu, these studies suggest that the use of 5-methyl-H4PteGlu would not be advantageous over that of 5-formyl-H4PteGlu in combination regimens with the fluoropyrimidines.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7522978     DOI: 10.1007/bf00685660

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  26 in total

1.  Effect of 5, 10-methylenetetrahydrofolate on the dissociation of 5-fluoro-2'-deoxyuridylate from thymidylate synthetase: evidence for an ordered mechanism.

Authors:  P V Danenberg; K D Danenberg
Journal:  Biochemistry       Date:  1978-09-19       Impact factor: 3.162

2.  Refractory metastatic breast cancer: salvage therapy with fluorouracil and high-dose continuous infusion leucovorin calcium.

Authors:  J H Doroshow; L Leong; K Margolin; B Flanagan; D Goldberg; M Bertrand; S Akman; B Carr; O Odujinrin; E Newman
Journal:  J Clin Oncol       Date:  1989-04       Impact factor: 44.544

3.  Relationship of cellular folate cofactor pools to the activity of 5-fluorouracil.

Authors:  M B Yin; S F Zakrzewski; M T Hakala
Journal:  Mol Pharmacol       Date:  1983-01       Impact factor: 4.436

Review 4.  Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma.

Authors:  M A Poon; M J O'Connell; C G Moertel; H S Wieand; S A Cullinan; L K Everson; J E Krook; J A Mailliard; J A Laurie; L K Tschetter
Journal:  J Clin Oncol       Date:  1989-10       Impact factor: 44.544

5.  Comparison of the conversion of 5-formyltetrahydrofolate and 5-methyltetrahydrofolate to 5,10-methylenetetrahydrofolates and tetrahydrofolates in human colon tumors.

Authors:  J A Houghton; L G Williams; S S de Graaf; P J Cheshire; I W Wainer; P Jadaud; P J Houghton
Journal:  Cancer Commun       Date:  1989

6.  Relationship between dose rate of [6RS]Leucovorin administration, plasma concentrations of reduced folates, and pools of 5,10-methylenetetrahydrofolates and tetrahydrofolates in human colon adenocarcinoma xenografts.

Authors:  J A Houghton; L G Williams; S S de Graaf; P J Cheshire; J H Rodman; D C Maneval; I W Wainer; P Jadaud; P J Houghton
Journal:  Cancer Res       Date:  1990-06-15       Impact factor: 12.701

7.  Influence of dose of [6RS]leucovorin on reduced folate pools and 5-fluorouracil-mediated thymidylate synthase inhibition in human colon adenocarcinoma xenografts.

Authors:  J A Houghton; L G Williams; P J Cheshire; I W Wainer; P Jadaud; P J Houghton
Journal:  Cancer Res       Date:  1990-07-01       Impact factor: 12.701

8.  Modulation of fluoropyrimidines: role of dose and schedule of leucovorin administration.

Authors:  Z G Zhang; A Harstrick; Y M Rustum
Journal:  Semin Oncol       Date:  1992-04       Impact factor: 4.929

9.  Treatment of advanced colorectal and gastric adenocarcinomas with 5-fluorouracil and high-dose folinic acid.

Authors:  D Machover; E Goldschmidt; P Chollet; G Metzger; J Zittoun; J Marquet; J M Vandenbulcke; J L Misset; L Schwarzenberg; J B Fourtillan
Journal:  J Clin Oncol       Date:  1986-05       Impact factor: 44.544

10.  Pharmacokinetics of leucovorin (D,L-5-formyltetrahydrofolate) after intravenous injection and constant intravenous infusion.

Authors:  J A Straw; E M Newman; J H Doroshow
Journal:  NCI Monogr       Date:  1987
View more
  1 in total

1.  Pharmacologic modulation of 5-fluorouracil by folinic acid and pyridoxine for treatment of patients with advanced breast carcinoma.

Authors:  David Machover; Emma Goldschmidt; Wathek Almohamad; Vincent Castagné; Julien Dairou; Christophe Desterke; Léa Gomez; Yann Gaston-Mathé; Claude Boucheix
Journal:  Sci Rep       Date:  2022-05-31       Impact factor: 4.996

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.